Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27628883 | 0.87 | KDM4E (0.78) | KDM4EMAPK1MAPTALDH1A1TDP1 | |
| SCHEMBL18479755 | 0.85 | KDM4E (0.76) | KDM4EMAPK1MAPTALDH1A1TDP1 | |
| SCHEMBL4705592 | 0.84 | KDM4E (0.62) | KDM4EMAPK1MAPTALDH1A1TDP1 | |
| SCHEMBL15331425 | 0.84 | MAPK1 (0.76) | KDM4EMAPK1MAPTALDH1A1TDP1 | |
| SCHEMBL18990660 | 0.84 | KDM4E (0.65) | KDM4EMAPK1MAPTALDH1A1TDP1 | |
| SCHEMBL24113579 | 0.82 | MAPK1 (0.74) | KDM4EMAPK1MAPTALDH1A1LMNA | |
| SCHEMBL18479757 | 0.82 | KDM4E (0.76) | KDM4EMAPK1MAPTALDH1A1TDP1 | |
| SCHEMBL16391745 | 0.82 | KDM4E (0.64) | KDM4EMAPK1MAPTALDH1A1TDP1 | |
| SCHEMBL18990354 | 0.82 | KDM4E (0.67) | KDM4EMAPK1MAPTALDH1A1TDP1 | |
| SCHEMBL16028019 | 0.82 | KDM4E (0.67) | KDM4EMAPK1MAPTALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578073-B2 | Xanthine analogs as potent anti-West Nile viral agents | SOUTHERN RESEARCH INSTITUTE (US) | 2023-02-14 | — | — | US | disclosed |
| US-20200399271-A1 | XANTHINE ANALOGS AS POTENT ANTI-WEST NILE VIRAL AGENTS | OREGON HEALTH AND SCIENCE UNIVERSITY | 2020-12-24 | — | — | US | disclosed |
| US-20120142712-A1 | 8-(3-AMINO-PIPERIDIN-1-YL)-XANTHINES, THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICALS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-8106060-B2 | 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-7820815-B2 | for preventing or treating disorders connected with an increased DPP-IV activity, especially of diabetes mellitus type I or type II, prediabetes, or reduction of glucose tolerance; 1-[(4-methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-26 | — | — | US | disclosed |
| US-20090192314-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 8-(3-AMINOPIPERIDIN-1YL)-XANTHINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-30 | — | — | US | disclosed |
| WO-2007014886-A1 | HYDROCHLORIDES AND HYDRATES OF 1-[(3-CYANOPYRIDIN-2-YL)METHYL]-3-METHYL-7-(2-BUTYN-1-YL)-8-(3-AMINOPIPERIDIN-1-YL)XANTHINE, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027168-A1 | 8-(3-AMINO-PIPERIDIN-1-YL)-XANTHINES, THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICALS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192314-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 8-(3-AMINOPIPERIDIN-1YL)-XANTHINES | UGT1A8, XDH, CYP2C8 | KDM4E 1956/4885MAPK1 1995/4885MAPT 2197/4885 |
| US-20070027168-A1 | 8-(3-AMINO-PIPERIDIN-1-YL)-XANTHINES, THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICALS | PDE8B, PDE8A, XDH | KDM4E 1953/4885MAPK1 2186/4885MAPT 1612/4885 |
| US-20200399271-A1 | XANTHINE ANALOGS AS POTENT ANTI-WEST NILE VIRAL AGENTS | XDH, PNP, MAVS | KDM4E 1167/4885MAPK1 2053/4885MAPT 872/4885 |
| US-11578073-B2 | Xanthine analogs as potent anti-West Nile viral agents | XDH, PNP, MAVS | KDM4E 1167/4885MAPK1 2053/4885MAPT 872/4885 |
| US-20120142712-A1 | 8-(3-AMINO-PIPERIDIN-1-YL)-XANTHINES, THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICALS | PDE8B, PDE8A, XDH | KDM4E 1953/4885MAPK1 2186/4885MAPT 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.